Safety and Efficacy Study of PI3K Delta Inhibitor in Autoimmune Hemolytic Anemia Patients Who Failed Two-round Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Study of PI3K Delta Inhibitor in Autoimmune Hemolytic Anemia Patients Who Failed Two-round Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial
DiscussionThe CAMARO trial investigates whether treatment with MMF and prednisolone increases the proportion of patients in remission compared with azathioprine and prednisolone as the current standard treatment strategy. In addition, we reflect on the challenges of conducting a randomized trial in rare diseases.Trial registrationEudraCT2016-001038-91. Prospectively registered on 18 April 2016.Graphical Abstract (Source: Trials)
Source: Trials - December 13, 2022 Category: Research Source Type: clinical trials
Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial
ConclusionThe offer to use the SPIN-HAND Program did not improve hand function. Low offer uptake, program access, and minimal usage among those who accessed the program limited our ability to determine if using the program would improve function. To improve engagement, the program could be tested in a group format or as a resource to support care provided by a physical or occupational therapist.Trial registrationNCT03419208. Registered on February 1, 2018. (Source: Trials)
Source: Trials - December 12, 2022 Category: Research Source Type: clinical trials
